InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime

InspireMD

04/11/2025 12:13

Overview

InspireMD Q3 revenue grows 39% yr/yr, beating analyst expectations

Net income for Q3 beats analyst estimates despite larger net loss

Company attributes revenue growth to U.S. launch and international market penetration

Outlook

InspireMD highlights strong demand for its CGuard Prime globally

Company emphasizes strategic focus on U.S. commercial expansion

InspireMD strengthens financial position with $58 mln in gross proceeds

Result Drivers

U.S. LAUNCH - Successful U.S. commercial launch of CGuard Prime carotid stent system contributed significantly to revenue growth

INTERNATIONAL PENETRATION - Increased penetration in international markets boosted revenue

OPERATING EXPENSES - Rise in operating expenses due to U.S. personnel expansion and establishment of U.S. headquarters

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$2.52 mln
$1.76 mln (2 Analysts)
Q3 Net Income
Beat
-$12.71 mln
-$14.60 mln (2 Analysts)
Q3 Income From Operations
Beat
-$13.05 mln
-$14.60 mln (2 Analysts)
Q3 Basic EPS
-$0.17
Q3 Gross Profit
$864,000
Q3 Operating Expenses
$13.91 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for InspireMD Inc is $4.50, about 49.1% above its November 3 closing price of $2.29

Press Release: ID:nGNX9JHY2S

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)